- Home
- CISO vs MRSN Comparison
CISO vs MRSN Comparison
Compare CISO & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- MRSN
- Stock Information
- Founded
- CISO 2015
- MRSN 2001
- Country
- CISO United States
- MRSN United States
- Employees
- CISO N/A
- MRSN N/A
- Industry
- CISO Computer Software: Prepackaged Software
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CISO Technology
- MRSN Health Care
- Exchange
- CISO Nasdaq
- MRSN Nasdaq
- Market Cap
- CISO 31.4M
- MRSN 37.0M
- IPO Year
- CISO N/A
- MRSN 2017
- Fundamental
- Price
- CISO $1.29
- MRSN $7.15
- Analyst Decision
- CISO
- MRSN Strong Buy
- Analyst Count
- CISO 0
- MRSN 3
- Target Price
- CISO N/A
- MRSN $33.00
- AVG Volume (30 Days)
- CISO 685.4K
- MRSN 62.6K
- Earning Date
- CISO 11-17-2025
- MRSN 11-12-2025
- Dividend Yield
- CISO N/A
- MRSN N/A
- EPS Growth
- CISO N/A
- MRSN N/A
- EPS
- CISO N/A
- MRSN N/A
- Revenue
- CISO $28,792,765.00
- MRSN $34,769,000.00
- Revenue This Year
- CISO N/A
- MRSN N/A
- Revenue Next Year
- CISO N/A
- MRSN N/A
- P/E Ratio
- CISO N/A
- MRSN N/A
- Revenue Growth
- CISO N/A
- MRSN 16.14
- 52 Week Low
- CISO $0.30
- MRSN $5.21
- 52 Week High
- CISO $3.84
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- CISO 68.68
- MRSN 47.47
- Support Level
- CISO $1.21
- MRSN $7.04
- Resistance Level
- CISO $1.47
- MRSN $7.49
- Average True Range (ATR)
- CISO 0.11
- MRSN 0.44
- MACD
- CISO 0.04
- MRSN 0.00
- Stochastic Oscillator
- CISO 70.30
- MRSN 36.53
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.